Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient

Drive gene mutation positive non‐small cell lung cancer achieves reliable clinical responses to subsequent target therapy. However, most patients will inevitably develop disease progression with multiple treatment failure. Next generation sequencing can identify clear resistance mechanisms. We repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yijuan, Xiao, Lili, Yang, Nong, Zhang, Yongchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501016/
https://www.ncbi.nlm.nih.gov/pubmed/30788907
http://dx.doi.org/10.1111/1759-7714.13015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501016/
https://www.ncbi.nlm.nih.gov/pubmed/30788907
http://dx.doi.org/10.1111/1759-7714.13015

Ejemplares similares